Pfizer Inc (PFE.N)
37.01USD
11:01pm IST
$0.33 (+0.90%)
$36.68
$36.76
$37.06
$36.75
1,837,231
7,532,012
$39.43
$31.67
About
Overall
| Beta: | 0.99 |
| Market Cap(Mil.): | $214,682.30 |
| Shares Outstanding(Mil.): | 5,955.13 |
| Dividend: | 0.32 |
| Yield (%): | 3.55 |
Financials
| PFE.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.26 | 30.95 | 32.74 |
| EPS (TTM): | 1.37 | -- | -- |
| ROI: | 6.00 | 14.84 | 14.38 |
| ROE: | 13.80 | 16.34 | 16.07 |
BRIEF-Pfizer Inc Declares 34 Cent Q2 Dividend
* PFIZER INC - PRELIMINARY RESULTS FROM ANNUAL MEETING OF SHAREHOLDERS INDICATE THAT CO'S 12 DIRECTOR NOMINEES WERE RE-ELECTED TO ONE-YEAR TERMS
Shire willing to back $64 billion Takeda bid, market signals doubts
LONDON/NEW YORK/TOKYO Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. | Video
Shire willing to back $64 billion Takeda bid, market signals doubts
LONDON/NEW YORK/TOKYO Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. | Video
UPDATE 10-Shire willing to back $64 bln Takeda bid, market signals doubts
* Takeda shares down 7 pct, Shire off 2.8 pct (Adds Shire shares closing down, more on pharma industry M&A)
FDA declines to approve Pfizer biosimilar of Roche's cancer drug
Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.
UPDATE 1-FDA declines to approve Pfizer biosimilar of Roche's cancer drug
April 23 Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.
BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba® (Meningococcal Group B Vaccine)
* PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR TRUMENBA® (MENINGOCOCCAL GROUP B VACCINE) FOR THE PREVENTION OF INVASIVE MENINGOCOCCAL B DISEASE IN CHILDREN AGES 1 TO 9 YEARS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
FDA declines to approve Pfizer's biosimilar to Roche's cancer drug
April 23 Pfizer Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve the company's biosimilar to Roche's breast cancer drug, Herceptin, and sought additional technical information. The company said the information requested by the FDA does not relate to safety or clinical data submitted in the application. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)
BRIEF-Pfizer: EU Approves Mylotarg With Chemotherapy To Treat Acute Myeloid Leukemia
* MYLOTARG™ APPROVED IN THE EU FOR THE TREATMENT OF PREVIOUSLY UNTREATED, DE NOVO, CD33-POSITIVE ACUTE MYELOID LEUKEMIA IN COMBINATION WITH CHEMOTHERAPY
BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar
* PFIZER INC - IN CRL, FDA HIGHLIGHTED NEED FOR ADDITIONAL TECHNICAL INFORMATION
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $128.84 | +2.08 |
| Novartis AG (NOVN.S) | CHF76.10 | +0.86 |
| Merck & Co., Inc. (MRK.N) | $59.53 | -0.10 |
| Roche Holding Ltd. (ROG.S) | CHF218.10 | +0.35 |
| Roche Holding Ltd. (RO.S) | CHF223.00 | +0.40 |
| Abbott Laboratories (ABT.N) | $59.15 | +0.50 |
| Bayer AG (BAYGn.DE) | €97.34 | -0.13 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €66.31 | +0.44 |
| AstraZeneca plc (AZN.L) | 4,992.00 | +1.00 |
Estimates